Brief: Talphera Announces Agreement With The FDA For Prior Approval Supplement Review To Reduce The Number Of Patients In The the NEPHRO CRRT Study
14/01/2025 13:31
Jan 14 (Reuters) - Talphera Inc TLPH.O :
* TALPHERA ANNOUNCES AGREEMENT WITH THE FDA FOR PRIOR
APPROVAL
SUPPLEMENT REVIEW TO REDUCE THE NUMBER OF PATIENTS IN THE NEPHRO
CRRT STUDY
* TALPHERA INC: FDA AGREED TO TWO ADDITIONAL PROTOCOL
CHANGES
EXPECTED TO ACCELERATE ENROLLMENT IN NEPHRO CRRT STUDY
Source text: ID:nPnc8Wxjta
Further company coverage: TLPH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Talphera
See all newsTalphera Inc reports results for the quarter ended June 30 - Earnings Summary
Talphera Inc expected to post a loss of 7 cents a share - Earnings Preview
Talphera Q1 net loss narrows as costs rise on higher development spending
Talphera Q4 net loss widens as operating expenses rise
Brief: Talphera Announces 50% Enrollment Milestone In Ongoing Nephro-Crrt Registrational Trial